© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 22, 2018
The drug is approved as a treatment for adult patients with newly-diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
September 13, 2018
Moxetumomab pasudotox (Lumoxiti, AstraZeneca)is approved for adults with relapsed or refractory HCL who received at least 2 prior systemic therapies, including treatment with a purine nucleoside analog.
High Relapse Rate After Discontinuing Antiviral Therapy for HBV Patients With Cirrhosis
Insomnia, Hypersomnia Identified as Symptoms of Long COVID Syndrome
Study Evaluates Insomnia and Suicidality Among Healthcare Workers During COVID-19 Pandemic